None
Quote | Dyne Therapeutics Inc. (NYSE:DYN)
Last: | $ |
---|---|
Change Percent: | -2.51% |
Open: | $13.12 |
Close: | $12.81 |
High: | $13.18 |
Low: | $12.76 |
Volume: | 22,175,203 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Dyne Therapeutics Inc. (NYSE:DYN)
2024-06-24 16:00:09 ET Eun Yang from Jefferies issued a price target of $42.00 for DYN on 2024-06-24 12:31:00. The adjusted price target was set to $42.00. At the time of the announcement, DYN was trading at $35.94. The overall price target consensus is at $38.14 with hi...
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Po...
Message Board Posts | Dyne Therapeutics Inc. (NYSE:DYN)
Subject | By | Source | When |
---|---|---|---|
Share structure TSX:DNG | MWM | investorshub | 10/27/2010 1:08:55 PM |
The company began the year with a milling | MWM | investorshub | 10/14/2010 3:41:17 AM |
Next move ? | drluck | investorshub | 12/14/2009 2:00:03 AM |
Who is running this show? If I set | Rock_E_Bottom | investorshub | 01/23/2007 11:29:33 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-06-24 16:00:09 ET Eun Yang from Jefferies issued a price target of $42.00 for DYN on 2024-06-24 12:31:00. The adjusted price target was set to $42.00. At the time of the announcement, DYN was trading at $35.94. The overall price target consensus is at $38.14 with hi...
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new preclinical data in a Po...
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage muscle disease company focuse...